|  |  |  |  |
| --- | --- | --- | --- |
| Author | Titel of the systematic review | Study design | RCT's retrieved |
| Shelley 20101 | Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses | SR+MA | Kaasinen 20002 |
|   | Bilen 20003 |
|   | Sekine 20014 |
|   | Au 20015 |
|   |   | De Reijke 20056 |
|   |   | Hinotsu 20067 |
|   |   | Van der Meijden 20018 |
|   |   | Lamm 20009 |
|   |   | Palou 200110 |
|   |   | Ojea 200711 |
|   |   | Friedrich 200712 |
|   |   | Di Stasi 200613  |
|   |   | Di Stasi 200314 |
| Shang 201115 | Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer | SR+MA | Cheng 200516 |
|   | Sylvester 201017 |
| Jones 201218  | Intravesical gemcitabine for non-muscle invasive bladder cancer | SR | Porena 201019 |
|   | Böhle 200920 |
| Perlis 201321 | Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review | SR+MA | Rajala 200222 |
|   | Okamura 200223 |
|   | EL-Ghobashy 200724 |
|   | Berrum-Svennung 200825 |
|   | Gudjonsson 200926  |
|   | De Nunzio 201127 |
| Li 201428  | Long-term versus short-term introvesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis of the published results of randomized clinical trials | SR+MA | Nomata 200229 |
|   | Koga 200430  |
|   | Kuroda 200431 |
|   | Isbarn 2008 (part1 & 2)32 |
|   | Hendricksen 200833 |
|   | Serretta 201034 |
|   | Mitsumori 200435 |
| Zeng 201536 | Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis | SR+MA | Inamoto 201337 |
|   | Vijjan 200638 |
|   | Agrawal 200739 |
|   | Oddens 201340 |
| Cui 201641  | Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis | SR+MA | Kaasinen 200342 |
|   | Cai 200843 |
|   | Gülpınar 201244 |
|   | Solsona 201545 |
|   |   |
| Sylvester 201646 | Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? | SR+IPD-MA | Barghi 200647 |
|   |   |
|   |   |
|   |   |
|   |   |
|   |   |
|   |   |
|   |   |
| Chou 201748 | Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis | SR+MA | Arends 201649 |
|   |   |
|   |   |
| Shepherd 201750 | Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer | SR+MA | Nepple 201051 |
|   |   |
|   |   |
|   |   |
| Jung 201752 | Intravesical electromotive drug administration for non-muscle invasive bladder cancer | SR | Di Stasi 201153 |
|   |   |
| Quan 201754 | Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials | SR+MA | Martinez-Pinneiro 200255 |
|   | Martinez-Pinneiro 200556 |
|   | Sengiku 2013 |
|   | Rentsch 2014 |
|   | Hinotsu 2011 |
|   | Martinez-Pineiro 201557 |
|   | Nakai 201658 |
| Boehm 201759 | Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis | SR+MA | Gårdmark 200760 |
|   | Hemdan 201461 |
|   | Järvinen 201262 |
|   | Järvinen 200963 |
|   | Koga 201064 |
| Mahran 201865 | Bladder irrigation after transurethral resection of superficial bladder cancer: a systematic review of the literature | SR+MA | Bijalwan 201766 |
|   | Onishi 201767 |
|   |  |
| Van Hemelrijck 201968 | Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review | SR | Huang 201569 |
|   |   |
|   |   |
| Uhlig 201870 | Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis | SR+MA | RCTs ALREADY INCLUDED |
| Chen 201871 | Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials | SR+MA | RCTs ALREADY INCLUDED |
| Tabayoyong 201872 | Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer | SR | RCTs ALREADY INCLUDED |
| Deng 201773 | Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer | SR | RCTs ALREADY INCLUDED |
|  |  |  |  |
| SR- systematic review; MA- meta-analysis;  |  |  |

REFERENCES

1. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses. *Cancer Treatment Reviews*. 2010;36(3):195-205. doi:10.1016/j.ctrv.2009.12.005

2. Kaasinen E, Rintala E, Pere A-K, et al. WEEKLY MITOMYCIN C FOLLOWED BY MONTHLY BACILLUS CALMETTE-GUERIN OR ALTERNATING MONTHLY INTERFERON-α2B AND BACILLUS CALMETTE-GUERIN FOR PROPHYLAXIS OF RECURRENT PAPILLARY SUPERFICIAL BLADDER CARCINOMA. *Journal of Urology*. 2000;164(1):47-52. doi:10.1016/S0022-5347(05)67446-0

3. Bilen CYu, Ozen H, Aki. FAZI l T, AygUn C, Ekici S, Kendi S. Clinical experience with BCG alone versus BCG plus epirubicin. *Int J Urol*. 2000;7(6):206-209. doi:10.1046/j.1442-2042.2000.00176.x

4. Sekine H, Ohya K, Kojima S, Igarashi K, Fukui I. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. *Int J Urol*. 2001;8(9):483-486. doi:10.1046/j.1442-2042.2001.00355.x

5. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. *J Natl Cancer Inst*. 2001;93(8):597-604. doi:10.1093/jnci/93.8.597

6. de REIJKE TM, Kurth KH, Sylvester RJ, et al. BACILLUS CALMETTE-GUERIN VERSUS EPIRUBICIN FOR PRIMARY, SECONDARY OR CONCURRENT CARCINOMA IN SITU OF THE BLADDER: RESULTS OF A EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER—GENITO-URINARY GROUP PHASE III TRIAL (30906). *Journal of Urology*. 2005;173(2):405-409. doi:10.1097/01.ju.0000150425.09317.67

7. Hinotsu S, Akaza H, Isaka S, et al. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: A smoothed hazard analysis in a randomized prospective study. *Urology*. 2006;67(3):545-549. doi:10.1016/j.urology.2005.09.045

8. van der Meijden AP, Brausi M, Zambon V, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. *J Urol*. 2001;166(2):476-481. doi:10.1097/00005392-200108000-00016

9. Lamm DL, Blumenstein BA, Crissman JD, et al. MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY. *Journal of Urology*. 2000;163(4):1124-1129. doi:10.1016/S0022-5347(05)67707-5

10. Palou J, Laguna P, Millán-Rodríguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodríguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. *J Urol*. 2001;165(5):1488-1491.

11. Ojea A, Nogueira JL, Solsona E, et al. A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C. *European Urology*. 2007;52(5):1398-1406. doi:10.1016/j.eururo.2007.04.062

12. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence Rate Compared with Short-Term Intravesical Chemotherapy and Short-Term Therapy with Bacillus Calmette-Guérin (BCG) in Patients with Non–Muscle-Invasive Bladder Carcinoma. *European Urology*. 2007;52(4):1123-1130. doi:10.1016/j.eururo.2007.02.063

13. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol*. 2006;7(1):43-51. doi:10.1016/S1470-2045(05)70472-1

14. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical Electromotive Mitomycin C Versus Passive Transport Mitomycin C for High Risk Superficial Bladder Cancer: A Prospective Randomized Study. *Journal of Urology*. 2003;170(3):777-782. doi:10.1097/01.ju.0000080568.91703.18

15. Shang PF, Kwong J, Wang ZP, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. *Cochrane Database Syst Rev*. 2011;(5):CD006885. doi:10.1002/14651858.CD006885.pub2

16. Cheng CW, Chan SFP, Chan LW, et al. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. *Int J Urol*. 2005;12(5):449-455. doi:10.1111/j.1442-2042.2005.01064.x

17. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. *European Urology*. 2010;57(5):766-773. doi:10.1016/j.eururo.2009.12.024

18. Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Urology Group, ed. *Cochrane Database of Systematic Reviews*. Published online January 18, 2012. doi:10.1002/14651858.CD009294.pub2

19. Porena M, Del Zingaro M, Lazzeri M, et al. Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in High-Risk Superficial Bladder Cancer: A Randomised Prospective Study. *Urol Int*. 2010;84(1):23-27. doi:10.1159/000273461

20. Böhle A, Leyh H, Frei C, et al. Single Postoperative Instillation of Gemcitabine in Patients with Non-muscle-invasive Transitional Cell Carcinoma of the Bladder: A Randomised, Double-blind, Placebo-controlled Phase III Multicentre Study. *European Urology*. 2009;56(3):495-503. doi:10.1016/j.eururo.2009.06.010

21. Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. *Eur Urol*. 2013;64(3):421-430. doi:10.1016/j.eururo.2013.06.009

22. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E, the FINNBLADDER GROUP. Perioperative Single Dose Instillation of Epirubicin or Interferon-α After Transurethral Resection for The Prophylaxis of Primary Superficial Bladder Cancer Recurrence: A Prospective Randomized Multicenter Study—Finnbladder III Long-Term Results. *Journal of Urology*. 2002;168(3):981-985. doi:10.1016/S0022-5347(05)64556-9

23. Okamura K, Ono Y, Kinukawa T, et al. Randomized study of single early instillation of (2?R)-4?-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. *Cancer*. 2002;94(9):2363-2368. doi:10.1002/cncr.10496

24. El-Ghobashy S, El-Leithy TR, Roshdy MM, El-Ganzoury HM. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. *J Egypt Natl Canc Inst*. 2007;19(2):121-126.

25. Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmäng S. A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small Recurrences. *Journal of Urology*. 2008;179(1):101-106. doi:10.1016/j.juro.2007.08.166

26. Gudjónsson S, Adell L, Merdasa F, et al. Should All Patients with Non–Muscle-Invasive Bladder Cancer Receive Early Intravesical Chemotherapy after Transurethral Resection? The Results of a Prospective Randomised Multicentre Study. *European Urology*. 2009;55(4):773-780. doi:10.1016/j.eururo.2009.01.006

27. De Nunzio C, Carbone A, Albisinni S, et al. Long-term experience with early single Mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. *World J Urol*. 2011;29(4):517-521. doi:10.1007/s00345-011-0691-2

28. Li T, Xing Y, Liu S, Han X, Li W, Chen M. Long-term versus short-term introvesical chemotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis of the published results of randomized clinical trials. *J Huazhong Univ Sci Technol [Med Sci]*. 2014;34(5):706-715. doi:10.1007/s11596-014-1340-y

29. Nomata K, Noguchi M, Kanetake H, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. *Cancer Chemotherapy and Pharmacology*. 2002;50(4):266-270. doi:10.1007/s00280-002-0487-6

30. Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S. A Randomized Controlled Trial of Short-Term Versus Long-Term Prophylactic Intravesical Instillation Chemotherapy for Recurrence After Transurethral Resection of Ta/T1 Transitional Cell Carcinoma of the Bladder. *Journal of Urology*. 2004;171(1):153-157. doi:10.1097/01.ju.0000100386.07370.0a

31. Kuroda M, Niijima T, Kotake T, Akaza H, Hinotsu S, 6th Trial of the Japanese Urological Cancer Research Group. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. *Eur Urol*. 2004;45(5):600-605. doi:10.1016/j.eururo.2003.12.010

32. Isbarn H, Budäus L, Pichlmeier U, Conrad S, Huland H, Friedrich MG. Vergleich der Effektivität der Langzeitinstillation mit Mitomycin C gegen Kurzzeitprophylaxen mit MMC oder Bacillus Calmette-Guerin: Untersuchung bei Patienten mit nicht muskelinvasivem Urothelkarzinom der Harnblase. *Urologe*. 2008;47(5):608-615. doi:10.1007/s00120-008-1671-z

33. Hendricksen K, Witjes WPJ, Idema JG, et al. Comparison of Three Schedules of Intravesical Epirubicin in Patients with Non–Muscle-Invasive Bladder Cancer. *European Urology*. 2008;53(5):984-991. doi:10.1016/j.eururo.2007.12.033

34. Serretta V, Morgia G, Altieri V, et al. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer: MAINTENANCE OF EARLY INTRAVESICAL CHEMOTHERAPY FOR NMI-BC. *BJU International*. 2010;106(2):212-217. doi:10.1111/j.1464-410X.2009.09153.x

35. Mitsumori K, Tsuchiya N, Habuchi T, et al. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection. *BJU Int*. 2004;94(3):317-321. doi:10.1111/j.1464-410X.2004.04884.x

36. Zeng S, Yu X, Ma C, et al. Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. *Medicine*. 2015;94(49):e2176. doi:10.1097/MD.0000000000002176

37. Inamoto T, Ubai T, Nishida T, Fujisue Y, Katsuoka Y, Azuma H. Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison. *Urol Ann*. 2013;5(1):7. doi:10.4103/0974-7796.106873

38. Kapoor R, Dubey D, Srivastava A, et al. A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer. *Indian J Urol*. 2006;22(4):317. doi:10.4103/0970-1591.29117

39. Agrawal MS, Agrawal M, Bansal S, Agarwal M, Lavania P, Goyal J. The Safety and Efficacy of Different Doses of Bacillus Calmette Guérin in Superficial Bladder Transitional Cell Carcinoma. *Urology*. 2007;70(6):1075-1078. doi:10.1016/j.urology.2007.07.017

40. Oddens J, Brausi M, Sylvester R, et al. Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. *European Urology*. 2013;63(3):462-472. doi:10.1016/j.eururo.2012.10.039

41. Cui J, Wang W, Chen S, et al. Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis. *Medicine*. 2016;95(3):e2572. doi:10.1097/MD.0000000000002572

42. Kaasinen E, Wijkström H, Malmström P-U, et al. Alternating Mitomycin C and BCG Instillations versus BCG Alone in Treatment of Carcinoma in Situ of the Urinary Bladder: A Nordic Study. *European Urology*. 2003;43(6):637-645. doi:10.1016/S0302-2838(03)00140-4

43. Cai T, Nesi G, Tinacci G, et al. Can Early Single Dose Instillation of Epirubicin Improve Bacillus Calmette-Guerin Efficacy in Patients With Nonmuscle Invasive High Risk Bladder Cancer? Results From a Prospective, Randomized, Double-Blind Controlled Study. *Journal of Urology*. 2008;180(1):110-115. doi:10.1016/j.juro.2008.03.038

44. Gülpinar Ö, Halilioğlu AH, Gökçe Mİ, Göğüş Ç, Baltaci S. The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study. *Int braz j urol*. 2012;38(4):474-479. doi:10.1590/S1677-55382012000400006

45. Solsona E, Madero R, Chantada V, et al. Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guérin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non–Muscle-invasive Bladder Cancer in Intermediate- and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial. *European Urology*. 2015;67(3):508-516. doi:10.1016/j.eururo.2014.09.026

46. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? *Eur Urol*. 2016;69(2):231-244. doi:10.1016/j.eururo.2015.05.050

47. Barghi MR, Rahmani MR, Hosseini Moghaddam SMM, Jahanbin M. Immediate intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with low-risk superficial transitional cell carcinoma of bladder. *Urol J*. 2006;3(4):220-224.

48. Chou R, Selph S, Buckley DI, et al. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. *Journal of Urology*. 2017;197(5):1189-1199. doi:10.1016/j.juro.2016.12.090

49. Arends TJH, Nativ O, Maffezzini M, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer. *European Urology*. 2016;69(6):1046-1052. doi:10.1016/j.eururo.2016.01.006

50. Shepherd AR, Shepherd E, Brook NR. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Cochrane Urology Group, ed. *Cochrane Database of Systematic Reviews*. Published online March 8, 2017. doi:10.1002/14651858.CD012112.pub2

51. Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL, Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer. *Journal of Urology*. 2010;184(5):1915-1919. doi:10.1016/j.juro.2010.06.147

52. Jung JH, Gudeloglu A, Kiziloz H, et al. Intravesical electromotive drug administration for non-muscle invasive bladder cancer. Cochrane Urology Group, ed. *Cochrane Database of Systematic Reviews*. Published online September 12, 2017. doi:10.1002/14651858.CD011864.pub2

53. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. *The Lancet Oncology*. 2011;12(9):871-879. doi:10.1016/S1470-2045(11)70190-5

54. Quan Y, Jeong CW, Kwak C, Kim HH, Kim HS, Ku JH. Dose, duration and strain of bacillus Calmette–Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials. *Medicine*. 2017;96(42):e8300. doi:10.1097/MD.0000000000008300

55. Martínez-Pin˜eiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer: COMPARISON OF STANDARD BCG DOSE VS THREE-FOLD LOWER DOSE. *BJU International*. 2002;89(7):671-680. doi:10.1046/j.1464-410X.2002.02722.x

56. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, et al. HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL. *Journal of Urology*. 2005;174(4 Part 1):1242-1247. doi:10.1097/01.ju.0000173919.28835.aa

57. Martínez-Piñeiro L, Portillo JA, Fernández JM, et al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non–muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. *European Urology*. 2015;68(2):256-262. doi:10.1016/j.eururo.2015.02.040

58. Nakai Y, Anai S, Tanaka N, et al. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial. *Int J Urol*. 2016;23(10):854-860. doi:10.1111/iju.13167

59. Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. *Journal of Urology*. 2017;198(3):503-510. doi:10.1016/j.juro.2017.01.086

60. Gårdmark T, Jahnson S, Wahlquist R, Wijkström H, Malmström P-U. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. *BJU Int*. 2007;99(4):817-820. doi:10.1111/j.1464-410X.2006.06706.x

61. Hemdan T, Johansson R, Jahnson S, et al. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. *J Urol*. 2014;191(5):1244-1249. doi:10.1016/j.juro.2013.11.005

62. Järvinen R, Kaasinen E, Rintala E, Group TF. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. *Scand J Urol Nephrol*. 2012;46(6):411-417. doi:10.3109/00365599.2012.694906

63. Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. *Eur Urol*. 2009;56(2):260-265. doi:10.1016/j.eururo.2009.04.009

64. Koga H, Ozono S, Tsushima T, et al. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group: Maintenance intravesical BCG. *International Journal of Urology*. 2010;17(9):759-766. doi:10.1111/j.1442-2042.2010.02584.x

65. Mahran A, Bukavina L, Mishra K, et al. Bladder irrigation after transurethral resection of superficial bladder cancer: a systematic review of the literature. *Can J Urol*. 2018;25(6):9579-9584.

66. Bijalwan P, Pooleri GK, Thomas A. Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection. *Indian J Urol*. 2017;33(2):144-148. doi:10.4103/iju.IJU\_371\_16

67. Onishi T, Sasaki T, Hoshina A, Yabana T. Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. *Anticancer Res*. 2011;31(4):1471-1474.

68. Van Hemelrijck M, Sparano F, Josephs D, Sprangers M, Cottone F, Efficace F. Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. *BMC Urol*. 2019;19(1):86. doi:10.1186/s12894-019-0518-9

69. Huang W, Wang F, Wu C, Hu W. Efficacy and safety of pirarubicin combined with hyaluronic acid for non-muscle invasive bladder cancer after transurethral resection: a prospective, randomized study. *Int Urol Nephrol*. 2015;47(4):631-636. doi:10.1007/s11255-015-0940-1

70. Uhlig A, Strauss A, Seif Amir Hosseini A, et al. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. *Eur Urol Focus*. 2018;4(6):924-936. doi:10.1016/j.euf.2017.08.007

71. Chen S, Zhang N, Shao J, Wang X. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials. *Int J Surg*. 2018;52:248-257. doi:10.1016/j.ijsu.2018.02.045

72. Tabayoyong WB, Kamat AM, O’Donnell MA, et al. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. *Eur Urol Focus*. 2018;4(4):512-521. doi:10.1016/j.euf.2018.08.019

73. Deng T, Liu B, Duan X, Zhang T, Cai C, Zeng G. Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer. *Sci Rep*. 2017;7(1):3172. doi:10.1038/s41598-017-03421-5